These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28489578)

  • 1. Inhibiting translesion DNA synthesis as an approach to combat drug resistance to DNA damaging agents.
    Choi JS; Kim S; Motea E; Berdis A
    Oncotarget; 2017 Jun; 8(25):40804-40816. PubMed ID: 28489578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artificial Nucleosides as Diagnostic Probes to Measure Translesion DNA Synthesis.
    Choi JS; Berdis A
    Methods Mol Biol; 2019; 1973():237-249. PubMed ID: 31016706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translesion DNA Synthesis and Reinitiation of DNA Synthesis in Chemotherapy Resistance.
    Shilkin ES; Boldinova EO; Stolyarenko AD; Goncharova RI; Chuprov-Netochin RN; Smal MP; Makarova AV
    Biochemistry (Mosc); 2020 Aug; 85(8):869-882. PubMed ID: 33045948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An artificial nucleoside that simultaneously detects and combats drug resistance to doxorubicin.
    Choi JS; Berdis A
    Eur J Haematol; 2020 Feb; 104(2):97-109. PubMed ID: 31729766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of translesion synthesis DNA polymerases in DNA interstrand crosslink repair.
    Roy U; Schärer OD
    DNA Repair (Amst); 2016 Aug; 44():33-41. PubMed ID: 27311543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Senescent stromal cell-induced divergence and therapeutic resistance in T cell acute lymphoblastic leukemia/lymphoma.
    Habiel DM; Krepostman N; Lilly M; Cavassani K; Coelho AL; Shibata T; Elenitoba-Johnson K; Hogaboam CM
    Oncotarget; 2016 Dec; 7(50):83514-83529. PubMed ID: 27835864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?
    Yamanaka K; Chatterjee N; Hemann MT; Walker GC
    PLoS Genet; 2017 Aug; 13(8):e1006842. PubMed ID: 28817566
    [No Abstract]   [Full Text] [Related]  

  • 8. Translesion polymerase η is upregulated by cancer therapeutics and confers anticancer drug resistance.
    Tomicic MT; Aasland D; Naumann SC; Meise R; Barckhausen C; Kaina B; Christmann M
    Cancer Res; 2014 Oct; 74(19):5585-96. PubMed ID: 25125662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.
    Nowak D; Liem NL; Mossner M; Klaumünzer M; Papa RA; Nowak V; Jann JC; Akagi T; Kawamata N; Okamoto R; Thoennissen NH; Kato M; Sanada M; Hofmann WK; Ogawa S; Marshall GM; Lock RB; Koeffler HP
    Exp Hematol; 2015 Jan; 43(1):32-43.e1-35. PubMed ID: 25450514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin.
    Moreland NJ; Illand M; Kim YT; Paul J; Brown R
    Cancer Res; 1999 May; 59(9):2102-6. PubMed ID: 10232595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triptycenes: a novel synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, induce DNA cleavage and decrease the viability of leukemic cells in the nanomolar range in vitro.
    Perchellet EM; Magill MJ; Huang X; Brantis CE; Hua DH; Perchellet JP
    Anticancer Drugs; 1999 Sep; 10(8):749-66. PubMed ID: 10573208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
    Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
    Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the Translesion Synthesis Pathway for the Development of Anti-Cancer Chemotherapeutics.
    Korzhnev DM; Hadden MK
    J Med Chem; 2016 Oct; 59(20):9321-9336. PubMed ID: 27362876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Translesion DNA Synthesis as a Novel Therapeutic Strategy to Treat Brain Cancer.
    Choi JS; Kim CS; Berdis A
    Cancer Res; 2018 Feb; 78(4):1083-1096. PubMed ID: 29259011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A non-natural nucleoside with combined therapeutic and diagnostic activities against leukemia.
    Motea EA; Lee I; Berdis AJ
    ACS Chem Biol; 2012 Jun; 7(6):988-98. PubMed ID: 22390204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological roles of translesion synthesis DNA polymerases in eubacteria.
    Andersson DI; Koskiniemi S; Hughes D
    Mol Microbiol; 2010 Aug; 77(3):540-8. PubMed ID: 20609084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translesion synthesis of 1,3-GTG cisplatin DNA lesions.
    Schneider S; Reissner T; Ziv O; Livneh Z; Carell T
    Chembiochem; 2010 Jul; 11(11):1521-4. PubMed ID: 20533496
    [No Abstract]   [Full Text] [Related]  

  • 18. Tolerance of lesions in E. coli: Chronological competition between Translesion Synthesis and Damage Avoidance.
    Fuchs RP
    DNA Repair (Amst); 2016 Aug; 44():51-58. PubMed ID: 27321147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single amino acid governs enhanced activity of DinB DNA polymerases on damaged templates.
    Jarosz DF; Godoy VG; Delaney JC; Essigmann JM; Walker GC
    Nature; 2006 Jan; 439(7073):225-8. PubMed ID: 16407906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA polymerase θ specializes in incorporating synthetic expanded-size (xDNA) nucleotides.
    Kent T; Rusanov TD; Hoang TM; Velema WA; Krueger AT; Copeland WC; Kool ET; Pomerantz RT
    Nucleic Acids Res; 2016 Nov; 44(19):9381-9392. PubMed ID: 27591252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.